The Liver Care Clinics
3416 Old Greenwood Road · Fort Smith, AR 72903
3.3(23 Google reviews · 5 in past year)
Mercy Bariatric Center - Fort Smith · 7001 Rogers Avenue · Fort Smith, AR 72903
4.3· 3 Google reviews
Listing updated October 2, 2026
No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.
| Advertises semaglutide today | Not listed |
| Advertises tirzepatide today | Not listed |
| Telehealth visits | Not listed |
| Cash pay accepted | — |
| Accepts insurance — per practice website | Yes |
| Accepting new patients — per practice website | Yes |
"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.
Counts computed by RetaMaps from public Google reviews; most recent review 2024-08-08. Read the reviews themselves on the practice's Google listing.
Rated ★4.3 across 3 Google reviews. Of the 3 reviews we analyzed, 2 (67%) are positive (4–5★) and 0 (0%) are negative (1–2★).
Luis B.★★★★★2019-09-06Doctor Ferrari is a great doctor highly recommended you did my surgery mom surgery and sister surgery can't ask for any better results A++ doctor if you haven't got a chance to find a Bariatric doctor he's your guy
Analysis by RetaMaps of reviews on this practice's public Google Business listing; review themes are detected automatically and reviews reflect their authors' opinions. See all reviews on Google.
3416 Old Greenwood Road · Fort Smith, AR 72903
3.3(23 Google reviews · 5 in past year)
6108 South 31st Street · Fort Smith, AR 72908
5.0(84 Google reviews · 26 in past year)
3400 South 70th Street · Fort Smith, AR 72903
4.3(3 Google reviews · 1 in past year)
Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.
Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)
Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs